Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedSIR
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of metastatic breast cancer HER2-positive phenotype (confirmed by IHC 3 + or FISH positive)
Older than 18 years
Progressed to at least one prior treatment line for MBC with trastuzumab and / or lapatinib, either as monotherapy or in combination with chemotherapy or hormonal therapy schemes
Having the patient's complete medical history that contains all lines antiHER2 therapy treatment
Being a patient who initiated the combination of trastuzumab and lapatinib between January 2005 and December 2011
Inform the patient and get the signature of the informed consent
You may not be if
Not having phenotypic classification of the tumor by IHC or FISH test for HER2
Being a patient with HER2-negative phenotype(FISH negative or IHC in range \[0-2 +\] without FISH)
Being a patient who received the trastuzumab and/or lapatinib treatment (TL) in combination with chemotherapy
Being a patient who, since January 2012, began TL therapy for metastatic disease.
Clareo Health | Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib
